Additionally, the blockade of CTLA‐4 can enhance the anti‐HBV response and increase the expansion of HBV‐specific CD8+ T cells capable of producing IFN‐γ, uncovering its potential as a therapeutic target in HCC.204. This evidence concerns the gene CD8A and hepatocellular carcinoma.